

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1841		Email between Ketchum and Berry re DMC Lipid Monitoring Guideline with attachments (AMRN02702785-90)
1/8/2020		1842		Email between Soni and Ballantyne re Placebo controls with AMR101 & Lovaza
1/8/2020		1843		Subpoena To Testify at a Deposition in a Civil Action directed to Philip Lavin (N/A)
1/8/2020		1844		Letter From K&L Gates To P. Lavin re Consulting Agreement With Respect To U.S. Patent Application Serial Number (AMRN03140245-46)
1/8/2020		1845		CV Philip T. Lavin (PL-AMRN00000001)
1/8/2020		1846		U.S. Patent 9,389,893 B2 (Stavros et al.) (N/A)
1/8/2020		1847		Daly, et al., "Enteral Nutrition With Supplemental Arginine, RNA, And Omega-3 Fatty Acids In Patients After Operation: Immunologic, Metabolic, And Clinical Outcome," (1992). (N/A)
1/8/2020 <i>1/13/2020</i>	<i>1/13/2020</i>	1848	<i>Ketchum</i>	American Statistical Association 1986 Proceedings Of Biopharmaceutical

Date Marked	Date Admitted	Number	Witness	Description
				Section (N/A)
1/8/2020		1849		Lavin, "Practical Considerations In The Coordination Of Clinical Trials," Clinical Trials Issues And Approaches (1983). (N/A)
1/8/2020		1850		Menon, et al., "Sample Size Calculation For Poisson Endpoint Using The Exact Distribution Of Difference Between Two Poisson Random Variables," (2011). (N/A)
1/8/2020		1851		Title Methods Of Treating Hypertriglyceridemia - 3717958/67(AMRN03024311)
1/8/2020		1852		Request For Continued Examination And Reponse To Office Action Dated August 18, 2011 (AMRN03025234-255)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1853		Request for Type-B Meeting: Pre-IND Meeting (AMRN03105910-41)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1854		Email between Manku, Cunningham, Holmes, and Cooke re Japanese publications – translations with attachments (AMRN01688238-360)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1855		Email between Doogan, Manku, Osterloh, Cooke, and Lynch re Omacor

Date Marked	Date Admitted	Number	Witness	Description
				(Omega-3-Acid Ethyl Esters) – Current Clinical Trials (AMRN01672057-60)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1856		Email between Manku, Cooke, Doogan, Lynch, and Osterloh re Meeting with Mochida's internal R and D team, attaching Satoh 2007 and Mizuguchi 1993 references (AMRN01688641-53)
				Email between Manku, Cunningham, Holmes, and Cooke RE: (AMRN01688572-3)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1857		Email between Crutchley, Sedlack, and others re Amarin Expert Panel Meeting for AMR-101 (ethyl-EPA) Meeting Package and attaching Amarin Expert Panel Meeting Materials (AMRN0588927-9018)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1859		Presentation: Overview of Hypertriglyceridemia. AMR 101 Expert Panel Meeting, Boston (AMRN01574093-115)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1860		Email between Osterloh, Braeckman, Soni, Doogan, Crutchley, and Manku re 12-Dec-2008 Expert Panel Meeting Comments on AMR101 Phase 3 Studies and attaching Ian's Notes from Amarin's Expert Panel Meeting 12th December 2008 (AMRN01531053-58)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1861		Email from Manku to Cooke and Lynch re Final Slides for Boston attaching Boston Dec 12 08.ppt [Pleiotropic effects of EPA in Cardiovascular Diseases] (AMRN01688980-9008)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1862		Email between Doogan, Sedlack, and others re Final Slides for Arisaph

Date Marked	Date Admitted	Number	Witness	Description
				attaching Partnering Presentation V6 July 31st.ppt (AMRN01673821-924)
1/8/2020		1863		Defendants' Notice of Deposition of Dr. Michael Miller
1/8/2020		1864		Declaration of Michael Miller, MD, FACC, FAHA, FNLA, FASPC on Claim Construction [Dkt. 89-1]
1/8/2020		1865		Materials Considered [Dkt. 89-4]
1/8/2020		1866		Reply Declaration of Michael Miller, MD, FACC, FAHA, FNLA, FASPC on Claim Construction [Dkt. 113-1]
1/8/2020		1867		Curriculum Vitae of Michael Miller [Dkt. 89-3]
1/8/2020		1868		Email between Soni and Miller re Amarin (AMRN03022275-6)
1/8/2020		1869		DRAFT NOTES, Meeting with Michael Miller – University of Maryland School of Medicine (AMRN01017280-1)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1870		Dr. Michael Miller's Consulting time for Amarin (Sept thru Dec, 2010) (AMRN02739796)
1/8/2020		1871		Dr. Michael Miller's Consulting time for Amarin (Jan thru June, 2011) (AMRN02769565)
1/8/2020		1872		2014 Clinical Development Department Goals – Status 2014 (AMRN03121925-31)
1/8/2020		1873		Dr. Michael Miller's Consulting time for Amarin (July thru December, 2011) (AMRN01077327)
1/8/2020		1874		Email between Soni and Schwarzkopf attaching spreadsheet: KOL Contacts – 19Nov2010 (AMRN01638777-8)
1/8/2020		1875		Email between Ketchum and Miller re Available to touch base this afternoon? (AMRN02702696)
1/8/2020	1/13/2020	1876		Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 106:3143-3421 (2002) (AMRN00289915-290194)
1/8/2020		1877		Exhibit 18 to Plaintiffs' Opening Markman Brief [Dkt. 89-20 to 86-26],

Same as 989 Stipulated

Date Marked	Date Admitted	Number	Witness	Description
				Excerpts from the File History of U.S. Patent No. 8,293,727
1/8/2020		1878		Jacobson, et al. Hypertriglyceridemia and Cardiovascular Risk Reduction, Clinical Therapeutics 29(5):763-777 (2007). (ICOSAPENT_DFNDTS00010211-25)
1/8/2020		1879		Exhibit 28 to Plaintiffs' Opening Markman Brief [Dkt. 89-37], C. Baigent et al., Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90,056 Participants in 14 Randomised Trials of Statins, 366 LANCET 1267–78 (2005). (AMRN03130228-239)
1/8/2020		1880		Email between Doogan, Osterloh, and Cunningham re Test Message (AMRN01693774-6)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1881		Amarin Portfolio Review Meeting (AMRN02105815-23)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1882		Email between Osterloh, Doogan, Cunningham, and Cooke re CV strategy (AMRN01671955-59)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1883		EPA for Hypertriglyceridemia, Minutes of project team meeting (AMRN02263119-22)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1884		Email between Mallard, Cooke, Osterloh, Wood, Doogan, and Shilling

Date Marked	Date Admitted	Number	Witness	Description
				re Investor Calls and evidence to support EPA tg programme (AMRN02175481-2)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1885		Email between Osterloh, Doogan, Wood, Cooke, Cunningham, Boal, and Shilling re EOA Hypertriglyceridemia Project Status and Investor Due Diligence attaching EPA Briefing Document (AMRN0167916-33)
				Email between Osterloh and Wicker re Miraxion – US experts(PW-AMRN00000603-4)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1886		Email between Osterloh and Wicker re Amarin – Confidential (PW-AMRN00000192-3)
				Email between Osterloh, Morgan, and others re Agenda & EPA claim scenarios (PW-AMRN00001186-89)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1888		Ian's Notes from Amarin's Expert Panel Meeting (AMRN01531055-58)
				Hypertriglyceridemia Expert Panel Meeting (AMRN02088919-925)
1/8/2020 <i>1/15/2020</i>	<i>1/16/2020</i>	1890		Curriculum Vitae of Howard S. Weintraub (HW-AMRN0000001-11)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1892		Webpage: Howard Weintraub / NYU Langone Health, https://nyulangone.org/doctors/1457347767/howard-weintraub , last accessed
1/8/2020		1893		Consultancy Agreement (AMRN03115613-21)
1/8/2020		1894		Email between Soni and Weintraub RE: (AMRN01540795)
1/8/2020		1895		Dollars for Docs, Howard Weintraub, https://projects.propublica.org/docdollars/doctors/print/202475 , last accessed
1/8/2020		1896		Email between Rowe and Weintraub re question (AMRN02900115-17)
1/8/2020 1/28/2020	1/28/2020	1897		Declaration of Howard Weintraub Under 37 C.F.R. § 1.132, Application No. 12/702,889 (AMRN03058275-83)
1/8/2020		1898		K&L Gates unexecuted Consulting Agreement with Respect to U.S. Patent Application Serial Number 12/702,889 (AMRN03140226-7)
1/8/2020		1899		Canaccord Genuity Expert Call: Amrn 101, Marine Trial Data. Edited Transcript (AMRN02844821-4849)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1900		Email between Rowe and Weintraub re Canaccord Genuity consultation request – Hypertriglyceridemia and AMR101 (AMRN00768524-25)
1/8/2020		1901		Email between Weintraub and Rowe re everything still ok for tomorrow at 5pm et? (AMRN02894016-20)
1/8/2020		1902		Weintraub, Update on marine omega-3 fatty acids: Management of dyslipidemia and current omega-3 treatment options. Atherosclerosis 230:381-389 (2013). (AMRN02325273-81)
1/8/2020		1903		Wei and Jacobson, Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis. Curr Atheroscler Rep 13:474-483 (2011).
1/8/2020		1904		Jacobson, et al. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review. Journal of Clinical Lipidology 6:5-18 (2012). (AMRN00924808-21)
1/8/2020		1905		Applicant Initiated Interview Request Form, Application No. 12/702,889 (AMRN03058229-31)
1/8/2020 1/28/2020	1/28/2020	1906		Declaration of Howard Weintraub Under 37 C.F.R. §1.132 and Exhibits

Date Marked	Date Admitted	Number	Witness	Description
				(AMRN03059081-229)
1/8/2020		1907		Request for Continued Examination and Response to Office Action Dated August 18, 2011 (AMRN03059035-56)
1/8/2020		1908		Bays, et al. Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, placebo-controlled, Randomized, double-blind, 12-week study with an open-label Extension [MARINE] Trial), Am J Cardiol 108:682-690 (2011) (AMRN00482295-303)
1/8/2020		1909		Tomoyuki, et al. Research Report: Efficacy and Safety of Ethyl Icosapentate (Epadel®) Given for a Long Term against Hyperlipidemia. Prog. Med. 21: 457-467 (2001). (AMRN02203920-46)
1/8/2020		1910		Weintraub Invoice for Consultative Services July-August 2013. (AMRN02709601-2)
1/8/2020		1911		Email between Doyle and Weintraub re Confidential: Vascepa Advisory Committee (AMRN02576725-6)
1/8/2020		1912		Email between Bress and Weintraub re Confidential: Vascepa Advisory Committee (AMRN02585990-4)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1913		Declaration of Ronald H. Wharton, M.D., in Support of Defendants' Claim Construction [Dkt. 102-1]
1/8/2020		1914		Curriculum Vitae, Ronald H. Wharton M.D. [Dkt. 102-4]
1/8/2020		1915		Materials Considered in Declaration of Ronald Wharton in Support of Defendants' Responsive Claim Construction Brief [Dkt. 102-3]
1/8/2020		1916		Exhibit 4 to Defendants' Responsive Claim Construction Brief [Dkt. 102-6], Calabresi et al., Omacor in Familial Combined Hyperlipidemia: Effects on Lipids and Low Density Lipoprotein Subclasses, Atherosclerosis 148:387-96 (2000)
1/8/2020		1917		Exhibit 5 to Defendants' Responsive Claim Construction Brief [Dkt. 102-7], Mori et. al., The Independent Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Cardiovascular Risk Factors in Humans, Current Opinion Clinical Nutrition & Metabolic Care 9:95-104 (2006). (ICOSAPENT_DFNDTS00011016-25)
1/8/2020		1918		Exhibit 19 to Plaintiffs' Opening Markman Brief [Dkt. 89-27], Excerpts from the File History of U.S. Patent No. 8,293,728
1/8/2020		1919		Errata Sheet for the October 16, 23018 Transcript of Aaron Berg

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1920		Errata for the Deposition of Nicholas P. Godici, June 25, 2019
1/8/2020		1921		Errata Sheet for the June 19, 2019 Deposition Transcript of Ivan T. Hofmann
1/8/2020		1922		Errata Sheet for the Transcript of Rebecca Juliano, Ph.D.
1/8/2020		1923		Errata Sheet for the October 24, 2018 Transcript of Steven Ketchum, Ph.D.
1/8/2020		1924		Errata Sheet for the July 9, 2019 Transcript of John Kornak
1/8/2020		1925		Errata Sheet for the June 20, 2019 Transcript of Stephen Kunin
1/8/2020		1926		Errata Sheet for the September 21, 2018 Deposition of Philip T. Lavin
1/8/2020		1927		Errata Sheet for the June 27, 2019 Deposition of Peter Mathers

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1928		Errata Sheet for the February 15, 2018 Deposition of Michael Miller
1/8/2020		1929		Errata Sheet for the July 2, 2019 Deposition of Sean Nicholson
1/8/2020		1930		Errata Sheet for the July 2, 2019 Deposition of Jonathan I. Sheinberg
1/8/2020		1931		Errata Sheet for the September 14, 2018 Deposition of Howard S. Weintraub
1/8/2020		1932		Summary Minutes of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting (Oct. 16, 2013) ("Advisory Committee Minutes") (AMRN01400429-33)
1/8/2020 1/27/2020	1/21/2020	1933	10th <i>Stipulated by Plaintiff's attorney</i>	Agren et al., Fish Diet, Fish Oil and Docosahexaenoic Acid Rich Oil Lower Fasting and Postprandial Plasma Lipid Levels, 50 European J. Clinical Nutrition 765, 770 (1996) ("Agren"). (AMRN00289896-904)
1/8/2020		1934		Aung et al., Associations of Omega-3 Fatty Acid Supplement Use with Cardiovascular Disease Risks: Meta-Analysis of 10 Trials Involving 77,917 Individuals, 3 JAMA Cardiology 225 (2018). (AMRN03164724-32)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1935		Austin, Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond., Am J Epidemiol. 1989 Feb;129(2):249-59 (ICOSAPENT_DFNDT00016786-96)
1/8/2020		1936		21 C.F.R. § 312.22 (ICOSAPENT_DFNDT00018101-02)
1/8/2020		1937		21 C.F.R. § 314.3 (ICOSAPENT_DFNDT00018103-08)
1/8/2020		1938		21 U.S.C. § 355 (ICOSAPENT_DFNDT00018148-206)
1/8/2020		1939		35 U.S.C. §111
1/8/2020		1940		37 CFR §1.63
1/8/2020		1941		37 CFR §1.75
1/8/2020		1942		37 CFR 1.97

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1943		37 CFR 1.98
1/8/2020		1944		Manual of Patent Examining Procedure Eighth Edition, Revision No. 8
1/8/2020		1945		Manual of Patent Examining Procedure Eighth Edition, Revision No. 9
1/8/2020		1946		Bansal, et al., Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women, AMA. 2007 Jul 18;298(3):309-16 (ICOSAPENT_DFNDT00016285-ICOSAPENT_DFNDT00016292)
1/8/2020	1/13/2020	1947		Buckley et al., Circulating Triacylglycerol and ApoE Levels in Response to EPA and Docosahexaenoic Acid Supplementation in Adult Human Subjects, 92 British J. Nutrition 477 (2004) ("Buckley"). (AMRN00290275-81) Same as 997 Stipulated
1/8/2020		1948		Concin, et al., Mineral oil paraffins in human body fat and milk, 46(2) Food Chem Toxicol. 544-52, 551 (2008) ("Concin") (ICOSAPENT_DFNDT00016662-70)
1/8/2020	1/13/2020	1949		Conquer et al., Supplementation with an Algae Source of Docosahexaenoic Acid Increases (n-3) Fatty Acid Status and Alters Selected Risk Factors for Heart Disease in Vegetarian Subjects, 126 J. Nutrition 3032 (1996) ("Conquer"). (AMRN00290326) Same as 920 Stipulated

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1950		Claim construction order in this case on August 10, 2018 Order (D.I. 135)
1/8/2020		1951		Joint Claim Construction Prehearing Statement Exhibit A: Constructions of the Claim Terms on which Parties Agree (D.I. 83-2, September 29, 2017).
1/8/2020		1952		Cucuzzella, Why should we treat high triglycerides?, J Fam Pract. 2004 February; 53(2):138-156 (ICOSAPENT_DFNDT00017638-49)
1/8/2020 1/14/2020	1/14/2020	1953	Scheinberg	Amarin's Preliminary Validity Contentions
1/8/2020		1954		ECS/EAS Guidelines for the Management of Dyslipidemias, 32 Eur. Heart J. 1769–1818 (2011)
1/8/2020		1955		FDA Briefing Document, Endocrinologic and Metabolic Drugs, Advisory Committee Meeting (Oct. 16, 2013) (AMRN03106502-617)
1/8/2020		1956		Harris et al., Why do omega-3 fatty acids lower serum triglycerides?, 17 Curr. Opin. Lipidol. 387 (2006) (ICOSAPENT_DFNDT00018532-38)
1/8/2020 1/14/2020	1/14/2020	1957	Scheinberg	Dean G. Karalis, A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids, 34 ADV. THER. 300-323 (2017)

Date Marked	Date Admitted	Number	Witness	Description
				(ICOSAPENT_DFNDT00016590- ICOSAPENT_DFNDT00016613)
1/8/2020		1958		Lembo et al., Chronic Constipation, 349 N. Eng. J. Med 1360-8, 1364 (2003) (ICOSAPENT_DFNDT00016150- ICOSAPENT_DFNDT00016158)
				FDA, Approval Package NDA 21-654, Statistical Review (2004) (AMRN03059165-229)
1/8/2020 <i>1/14/2020</i>	<i>1/17/2020</i>	1960	<i>Schemberg</i>	Michael A. Miller, Disorders of Hypertriglyceridemia, in THE JOHNS HOPKINS TEXTBOOK OF DYSLIPIDEMIA 74 (Kwiterovich Jr. ed., 2009) (AMRN00291100-39)
1/8/2020 <i>1/27/2020</i>		1961		Rambjør et al., Eicosapentaenoic Acid Is Primarily Responsible for Hypotriglyceridemic Effect of Fish Oil in Humans, 31 Lipids S-45 (1996) (ICOSAPENT_DFNDTS00006763-69)
1/8/2020 <i>1/13/2020</i>		1962		REDUCE-IT Clinical Study Report (Feb. 27, 2019) (AMRN03168745)
<i>same as 501 Stipulated</i>				
1/8/2020		1963		Endocrine Society Releases Guidelines on Diagnosis and Management of Hypertriglyceridemia, 88(2) Am. Fam. Phys. 143-144 (July 2013)
1/8/2020 <i>1/13/2020</i>		1964		Westerveld et al., Effects of Low-Dose EPA-E on Glycemic Control, Lipid Profile, Lipoprotein(a), Platelet Aggregation, Viscosity, and Platelet and Vessel Wall Interaction in NIDDM, 16 Diabetes Care 683, 686 (1993)
<i>same as 1022 Stipulated</i>				

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1965		Classification of Hyperlipidaemias and Hyperlipoproteinaemias, Bulletin of the World Health Organization, 43(6): 891–915 (1970) (ICOSAPENT DFNDTS00007033-57)
1/8/2020		1966		Amarin Corp., Press Release, Amarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for Vascepa® (icosapent ethyl) to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark REDUCE-IT™ Cardiovascular Outcomes Study (Mar. 28, 2019), available at https://investor.amarincorp.com/news-releases/news-release-details/amarin-submitssupplemental-new-drug-application-snda-us-fda . (ICOSAPENT DFNDT00015568-70)
1/8/2020		1967		Blacher et al., Cardiovascular Effects of B-Vitamins and/or n-3 Fatty Acids: the Su.Fol.Om3 Trial, 167 Int'l J. Cardiology 508 (2013) (AMRN03164797-802)
1/8/2020		1968		Bonds et al., Effect of Long-Chain ω-3 Fatty Acids and Lutein + Zeaxanthin Supplements on Cardiovascular Outcomes: Results of the Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial, 174 JAMA Internal Med. 763 (2014) (AMRN00862631-39)
1/8/2020		1969		Email between Riedell and Dist:Sales Professionals re Rapid Overview Webcast Presentation with attachment (AMRN00866721-45)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1970		Bosch et al., n-3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia, 367 N. Eng. J. Med. 309 (2012) (AMRN03147161-70)
1/8/2020		1971		Bowman et al., Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus, 379 N. Eng. J. Med. 1540 (2018)(AMRN-PEXP-0000701-11)
1/8/2020		1972		Center for Drug Evaluation and Research, Vascepa® Statistical Review (May 17, 2012), (AMRN00291613-89)
1/8/2020		1973		Cowan G. Statistical Data Analysis. Oxford University Press; 1998. (ICOSAPENT_DFNDT00019836-20045)
1/8/2020		1974		DRL Label (DRLEEEPA 0095595-96)
1/8/2020		1975		Einvik et al., A Randomized Clinical Trial on n-3 Polyunsaturated Fatty Acids Supplementation and All-Cause Mortality in Elderly Men at High Cardiovascular Risk, 17 Eur. J. Cardiovascular Prevention & Rehabilitation 588 (2010) (AMRN02642567-72)
1/8/2020		1976		Epanova® Label (AMRN03129984-94)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1977		Fosamax Label (ICOSAPENT_DFNDT00015688-710)
1/8/2020		1978		Goodman MS. Biostatistics for clinical and public health research. Milton Park, Abingdon, Oxon ; New York, NY: Routledge; 2018. (ICOSAPENT_DFNDT00019255-835)
1/8/2020		1979		H.R. Rep. No. 98-857, pt. I (1984), reprinted in 1984 U.S.C.C.A.N. 2647-48 (ICOSAPENT_DFNDT00018272-314)
1/8/2020		1980		FDA Adverse Events Reporting System (FAERS) Public Dashboard https://fis.fda.gov/sense/app/d10be6bb-494e-4cd2-82e4-0135608ddc13/sheet/8eef7d83-7945-4091-b349-e5c41ed49f99/state/analysis . (ICOSAPENT_DFNDT00018067)
1/8/2020		1981		Chapter 5: Atherosclerosis Lipoprotein Entry and Modification Contents, https://wrhhs.org/chapter-5-atherosclerosis/2/ (ICOSAPENT_DFNDT00018371-81)
1/8/2020 1/14/2020	1/14/2020	1982	Budoff	https://www.vascepa.com/high-triglycerides-cause . (ICOSAPENT_DFNDT00018063-66)
1/8/2020		1983		Kromhout et al., n-3 Fatty Acids and Cardiovascular Events After

Date Marked	Date Admitted	Number	Witness	Description
				Myocardial Infarction, 363 N. Eng. J. Med. 2015 (2010) (AMRN01404742–01404753)
1/8/2020 <i>1/14/2020</i>	<i>1/14/2020</i>	1984	<i>Scheinberg</i>	Lamisil® Label (ICOSAPENT_DFNDT00015617-629)
				Levaquin® Label (ICOSAPENT_DFNDT00015630-687)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	1986	<i>Scheinberg</i> <i>Sten</i>	Lipitor Label (ICOSAPENT_DFNDT00015752-776)
				Manson et al., Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer, 380 N. Eng. J. Med. 23 (2019) (AMRN-PEXP-0000712–721)
1/8/2020		1988		Marcello Pagano, Kimberlee Gauveau. Principles of biostatistics. Chapman and Hall/CRC; 2018 (ICOSAPENT_DFNDT00020046-630)
				NDA No. 202057, FDA Approval Letter (July 26, 2012) (AMRN00482979-85)
1/8/2020		1990		Thomopoulos, Nick T. Thomopoulos. Probability distributions: with truncated, log and bivariate extensions (2018) (ICOSAPENT_DFNDT00019084-254)
1/8/2020		1991		Niacor® Label (AMRN-PEXP-0001667–72)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1992		Oberman, et al., Chapter 4 Lipoprotein Transport, PRINCIPLES AND MANAGEMENT OF LIPID DISORDERS: A PRIMARY CARE APPROACH. PHARMACOLOGIC THERAPY OF LIPID DISORDERS. Williams and Wilkins, Baltimore; 87–105 (1992)
1/8/2020		1993		Omacor® Approval Letter (ICOSAPENT_DFNDTS00006366–68)
1/8/2020		1994		Omtryg® Label (AMRN03130027–41)
1/8/2020		1995		ORIGIN Trial Investigators, Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE), 39 Diabetes Care 709 (2016)(AMRN-PEXP-0001737–44)
1/8/2020		1996		Oxycontin Label (ICOSAPENT_DFNDT00015571-616)
1/8/2020		1997		Rauch et al., OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction, 122 Circulation 2152 (2010) (AMRN01521522–30)
1/8/2020		1998		Roncaglioni et al., n-3 Fatty Acids in Patients with Multiple Cardiovascular

Date Marked	Date Admitted	Number	Witness	Description
				Risk Factors, 368 N. Eng. J. Med. 1800 (2013) (AMRN03147275-83)
1/8/2020		1999		Saxenda® Label (ICOSAPENT_DFNDT00015828-839)
1/8/2020		2000		Tricor® 2018 Label (ICOSAPENT_DFNDT00015777-814)
1/8/2020 <i>1/15/2020</i>	<i>1/15/2020</i>	2001	<i>Heineke</i>	U.S. Patent No. 10,278,936 (ICOSAPENT_DFNDT00017548-600)
1/8/2020		2002		Victoza® Label (ICOSAPENT_DFNDT00015815-827)
1/8/2020 <i>1/14/2020</i>	<i>1/14/2020</i>	2003	<i>Budoff</i>	Vital News Volume 3, Issue 1 March 2017 (AMRN03147654-57)
1/8/2020		2004		Vittinghoff E, Glidden, David V., Shiboski, Stephen C., McCulloch, Charles E. Regressionmethods in biostatistics: linear, logistic, survival, and repeated measures models. 2nd ed. New York: Springer; 2012. 509 p. (Statistics for biology and health). (ICOSAPENT_DFNDT00018558-19083)
1/8/2020 <i>1/28/2020</i>	<i>1/28/2020</i>	2005	<i>Totk</i>	Zocor® (simvastatin) 2007 label (ICOSAPENT_DFNDT00018539-57)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2006		Complaint for Patent Infringement, Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited v. Roxane Laboratories, Inc. and Hikma Pharmaceuticals PLC, Case No. 2:16-cv-02525, filed October 31, 2016
1/8/2020		2007		Answer, Affirmative Defenses, and Counterclaims, Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited v. Roxane Laboratories, Inc. and Hikma Pharmaceuticals PLC, Case No. 2:16-cv-02525-MMD-NJK, filed January 9, 2017
1/8/2020		2008		Complaint for Patent Infringement, Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited v. Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd., Case No. 2:16-cv-2562, filed November 4, 2016
1/8/2020		2009		Answer, Affirmative Defenses, and Counterclaims of Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Ltd., Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited v. Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd., Case No.: 2:14-cv-02562 / 2:16-cv-02525 (Consolidated), filed January 13, 2017
1/8/2020		2010		Orange Book at https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=002&Appl_No=202057&Appl_type=N , accessed April 22, 2019 (ICOSAPENT_DFNDT00016784-85)
1/8/2020		2011		Consolidation Order, filed November 7, 2017

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2012		https://www.news-medical.net/health/Hypertriglyceridemia-Cause-and-Symptoms.aspx , accessed April 29, 2019. (ICOSAPENT_DFNDT00016589)
1/8/2020		2013		https://www.jabfm.org/content/19/3/310 , accessed April 16, 2019. (ICOSAPENT_DFNDT00016579-88)
1/8/2020		2014		Sweeney, Mary Ellen T., and Romesh Khardori, "Hypertriglyceridemia Medication," Medscape, available at https://emedicine.medscape.com/article/126568-medication (ICOSAPENT_DFNDT00018035-42)
1/8/2020		2015		https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/statin-side-effects/art-20046013 (ICOSAPENT_DFNDT00016813-16)
1/8/2020		2016		https://www.medicalnewstoday.com/articles/8274.php , accessed April 25, 2019. (ICOSAPENT_DFNDT00016817-20)
1/8/2020		2017		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028601/ , accessed April 29, 2019. (ICOSAPENT_DFNDT00016834-43)
1/8/2020		2018		https://healthengine.com.au/info/fibrates , accessed April 29, 2019. (ICOSAPENT_DFNDT00016314-15)
1/8/2020		2019		Lipofen® FDA Label, revised November 2018, see https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021612s017lbl.pdf (ICOSAPENT_DFNDT00016614-21)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2020		https://medlineplus.gov/druginfo/meds/a601052.html , accessed May 9, 2019. (ICOSAPENT_DFNDT00016293-95)
1/8/2020		2021		https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.pr ocess&ApplNo=021656 (ICOSAPENT_DFNDT00016882-83)
1/8/2020		2022		http://tricortablets.com/ , accessed April 29, 2019 (ICOSAPENT_DFNDT00016146-47)
1/8/2020		2023		Lipofen, Drugs@FDA: FDA Approved Drugs Products https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=ove rview.process&ApplNo=021612 , accessed April 23, 2019 (ICOSAPENT_DFNDT00016622-23)
1/8/2020		2024		Triglide® FDA Label, revised May 2018, see https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021350s020lbl.pdf (ICOSAPENT_DFNDT00016884-900)
1/8/2020		2025		Triglide Drugs@FDA: FDA Approved Drugs Products https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=ove rview.process&ApplNo=021350 , accessed April 23, 2019 (ICOSAPENT_DFNDT00016901-02)
1/8/2020		2026		Antara® FDA Label, revised October 2018, see https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021695s018lbl.pdf (ICOSAPENT_DFNDT00016121-39)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2027		Antara Website, http://www.antararx.com/ , accessed April 23, 2019. (ICOSAPENT_DFNDT00016119-20)
1/8/2020		2028		Fenoglide® FDA Label, revised March 2019, see https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022118s009lbl.pdf (ICOSAPENT_DFNDT00016296-311)
1/8/2020		2029		Trilipix® FDA Label, revised November 2018, see https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022224s014lbl.pdf (ICOSAPENT_DFNDT00016908-27)
1/8/2020		2030		Triliplix Drugs@FDA: FDA Approved Drugs Products https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022224 (ICOSAPENT_DFNDT00016928-30)
1/8/2020		2031		Fabricor® FDA Label, revised May 2018, see https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022418s014lbl.pdf (ICOSAPENT_DFNDT00016316-33)
1/8/2020		2032		Fabricor Drugs@FDA: FDA Drug Products https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022418 , accessed April 24, 2019. (ICOSAPENT_DFNDT00016334-35)
1/8/2020		2033		Lopid® FDA Label, revised April 2017, see https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018422s056lbl.pdf (ICOSAPENT_DFNDT00016624-38)
1/8/2020		2034		LOPID, Drugs@FDA: FDA Approved Drugs

Date Marked	Date Admitted	Number	Witness	Description
				Products https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018422 , accessed April 24, 2019 (ICOSAPENT_DFNDT00016639-40)
1/8/2020		2035		Niaspan® FDA Label, revised February 2013, see https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020381s048lbl.pdf (ICOSAPENT_DFNDT00016671-99)
1/8/2020		2036		Niaspan Drugs@FDA: FDA Approved Drugs Products https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020381 (ICOSAPENT_DFNDT00016700-03)
1/8/2020		2037		https://www.niaspan.com/what-is-niaspan , accessed May 1, 2019. (ICOSAPENT_DFNDT00017635-37)
1/8/2020		2038		https://www.tevapharm.com/news/teva_announces_exclusive_launch_of_genic_niaspan_in_the_united_states_09_13.aspx , accessed April 25, 2019 (ICOSAPENT_DFNDT00016830)
1/8/2020	1/21/2020	2039	Hofmann	OH, Management of Hypertriglyceridemia, American Family Physician, https://www.aafp.org/afp/2007/0501/p1365.html (ICOSAPENT_DFNDT00016657-61)
<i>Subject to redaction</i>				
1/8/2020		2040		McKenney, Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia, https://www.ncbi.nlm.nih.gov/pubmed/17461707 ; (ICOSAPENT_DFNDT00016812)
1/8/2020		2041		Moloudizargari, Effects of the polyunsaturated fatty acids, EPA and

Date Marked	Date Admitted	Number	Witness	Description
				DHA, on hematological malignancies: a systematic reviewhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837752/, accessed May 8, 2019 (ICOSAPENT_DFNDT00016235-247)
1/8/2020		2042		Lovasa Drugs@FDA: FDA Approved Drugs Productshttps://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021654, accessed April 29, 2019 (ICOSAPENT_DFNDT00016644-560)
1/8/2020		2043		Reliant Pharmaceuticals, Inc., Pre- effective Amendment No. 3 to Form S- 1 dated August 10, 2007 (AMRN-PEXP-0006773-7098)
1/8/2020		2044		Koski, Omega-3-acid Ethyl Esters (Lovaza) For Severe Hypertriglyceridemia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683599/, accessed April 17, 2019 (ICOSAPENT_DFNDT00016704-10)
1/8/2020		2045		GSK to Acquire Reliant Pharmaceuticals for \$1.65B. https://www.genengnews.com/news/gsk-to-acquire-reliant-pharmaceuticals-for-1-65b/27018604/ (ICOSAPENT_DFNDT00016526-27)
1/8/2020		2046		Teva Announces First Approval and Launch of Generic Lovaza® Capsules in the United States. https://www.tevapharm.com/news/teva_announces_first_approval_and_launch_of_generic_lovaza_capsules_in_the_united_states_04_14.aspx, accessed April 30, 2019 (ICOSAPENT_DFNDT00016831-33)
1/8/2020		2047		S.2748 - Drug Price Competition and Patent Term Restoration Act of 1984.

Date Marked	Date Admitted	Number	Witness	Description
				https://www.congress.gov/bill/98th-congress/senate-bill/2748 , accessed April 26, 2019 (ICOSAPENT_DFNDT00016821-22)
1/8/2020		2048		Coster, The Waxman-Hatch Generic Drug Law. https://www.uspharmacist.com/article/the-waxman-hatch-generic-drug-law , accessed April 26, 2019 (ICOSAPENT_DFNDT00016563-78)
1/8/2020		2049		Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2013 (AMRN-PEXP-0005699-833)
1/8/2020 1/21/2020	1/21/2020	2050	Hofmann	Quarterly Financial Summary Q1 2013-Q4 2018(AMRN03171432) <i>Subject to redaction</i>
1/8/2020		2051		Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2012 (AMRN-PEXP-0005520-698)
1/8/2020		2052		Amarin Corporation plc, Second Quarter 2008 Earnings Call Transcript, https://seekingalpha.com/article/97385-amarin-corporation-plc-q2-2008-earningscall-transcript?part=single , accessed April 17, 2019 (ICOSAPENT_DFNDT00015890-95)
1/8/2020		2053		The Pharmacy Times article, dated August 15, 2009, "The Hatch-Waxman Act – 25 Years Later: Keeping the Pharmaceutical Scales Balances," https://www.pharmacytimes.com/publications/supplement/2009/genericsupplement0809/generic-hatchwaxman-0809 ,

Date Marked	Date Admitted	Number	Witness	Description
				accessed April 26, 2019 (ICOSAPENT_DFNDT00016548-62)
1/8/2020 1/17/2020	1/17/2020	2054	Hofmann	Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2018 (AMRN-PEXP-0007482-685) pin cite 72 subject to redaction
1/8/2020		2055		Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2011 (AMRN-PEXP-0005304-519)
1/8/2020		2056		Amarin Presentation, "2017 Operating Plan," (AMRN03151453-514)
1/8/2020 1/21/2020	1/21/2020	2057	Hofmann	Amarin Corporation plc, Fourth Quarter 2018 Earnings Call Transcript, see https://seekingalpha.com/article/4244867-amarin-corporation-plc-amrn-ceo-john-thero-q4-2018-results-earningscall-transcript?part=single , accessed April 17, 2019 (ICOSAPENT_DFNDT00015869-81)
1/8/2020		2058		Boris, John T., et al., "Lowering Sales on Slower Ramp & Execution Risk; Keener Focus on Shareholder Value Needed," SunTrust Robinson Humphrey (AMRN-PEXP-0007737-47)
1/8/2020		2059		Chen, Louise et al., "Don't Die of a Broken Heart; Physician Survey Shows How Vascepa Can Help," Cantor Fitzgerald. (AMRN-PEXP-0007220-54)
1/8/2020		2060		Diabetes Patient Advocacy Coalition, "How the FDA Drug Approval Process

Date Marked	Date Admitted	Number	Witness	Description
				Works," available at http://diabetespac.org/fda-drug-approval-process/ (AMRN-PEXP-0003460-65)
1/8/2020 1/21/2020	1/21/2020	2061	Hofmann	H.C. Wainwright & Co. Earnings Update, May 11, 2015 (ICOSAPENT_DFNDT00016540-47) pincite = 4 Subject to redaction
1/8/2020 1		2062		Fein, Andrew S., et al., "Embracing a Decidedly Non-Orphan Disease Company; Reit Buy and Raising PT to \$51," H.C. Wainwright & Co. (AMRN-PEXP-0007718-22)
1/8/2020		2063		Chen, Louise et al., "If You Had Any Concerns Going Into 2019, REDUCE-IT," Cantor Fitzgerald. (AMRN-PEXP-0007205-19)
1/8/2020		2064		Yee, Michael J. et al., "Easy and great tuck-in for pharma global salesforce," Jefferies Research Services (AMRN-PEXP-0007725-35)
1/8/2020 1/17/2020	1/17/2020	2065	Hofmann	H.C. Wainwright & Co. Earnings Update, dated February 26, 2016 (ICOSAPENT_DFNDT00016528-34) pincite 4 Subject to redaction
1/8/2020 1/17/2020	1/17/2020	2066	Hofmann	H.C. Wainwright & Co. Earnings Update, dated March 1, 2017 (ICOSAPENT_DFNDT00016535-39) pincite 2 - subject to redaction
1/8/2020 1/21/2020	1/21/2020	2067	Hofmann	Amarin NDTI Jan 08 to Nov 12 010819.xlsx, (AMRN-PEXP-0007099) subject to redaction

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020 <u>1/21/2020</u>	<u>1/21/2020</u>	2068	<u>Hofmann</u>	Complaint, Amarin Pharma, Inc. v. U.S. Food & Drug Admin., No. 1:15-cv-03588 (S.D.N.Y. May 7, 2015). (ICOSAPENT_DFNDT00016159-234) <u>Subject to redaction</u>
1/8/2020		2069		Opinion & Order, Amarin Pharma, Inc. v. U.S. Food & Drug Admin., No. 1:15-cv-03588 (S.D.N.Y. Aug. 7, 2015) (ICOSAPENT_DFNDT00016711-81)
1/8/2020		2070		Amarin Corporation plc, Third Quarter 2015 Earnings Call Transcript, see https://seekingalpha.com/article/3644706-amarins-amrn-ceo-john-thero-q3-2015-results-earnings-calltranscript?part=single , accessed May 6, 2019 (ICOSAPENT_DFNDT00016091-101)
1/8/2020		2071		Amarin Corporation plc, Form 10-Q, for the Quarter ended March 31, 2019, pg. 7, see https://www.sec.gov/Archives/edgar/data/897448/000156459019014555/amrn-10q_20190331.htm , accessed May 3, 2019 (ICOSAPENT_DFNDT00015949-6021)
1/8/2020		2072		Amarin Corporation plc, First Quarter 2019 Earnings Call Transcript, see https://seekingalpha.com/article/4258570-amarins-amrn-ceo-john-thero-q1-2019-results-earnings-calltranscript?part=single?part=single , accessed May 3, 2019 (ICOSAPENT_DFNDT00016068-80)
1/8/2020		2073		Amarin Corporation plc, Fourth Quarter 2015 Earnings Call Transcript, see https://seekingalpha.com/article/3931496-amarins-amrn-ceo-john-thero-q4-2015-results-earnings-

Date Marked	Date Admitted	Number	Witness	Description
				calltranscript?part=single, accessed April 29, 2019 (ICOSAPENT_DFNDT00016102-18)
1/8/2020		2074		Amarin Corporation plc, Presents at Cowen Health Care Conference, see https://seekingalpha.com/article/4248486-amarin-corporation-plc-amrn-presents-cowen-health-care-brokerconference-call-transcript?part=single , accessed May 7, 2019. (ICOSAPENT_DFNDT00015882-89)
1/8/2020		2075		GfK Presentation, "VASCEPA SFE, Q3 2017, Quantitative Research, Final Report Prepared for Amarin" September 1, 2017. (AMRN03152279-308)
1/8/2020		2076		PharmaSight Research Presentation, "Vascepa® New Promotional Campaign Exploration: Phase 1: Message Testing" (AMRN03152472-521)
1/8/2020		2077		AplusA Report, "Vascepa® (Icosapent ethyl), US Market Surveillance Study (ATU), Final Report of Findings," January 2016 v.2b (AMRN03151938-2047)
1/8/2020		2078		ZS Associates Presentation, "Vascepa Wave 2 PhysPulse Findings," (AMRN03151826-937)
1/21/2020	1/21/2020	2079	Hofmann	Amarin Corporation plc, First Quarter 2014 Earnings Call Transcript, see https://seekingalpha.com/article/2206783-amarins-amrn-ceo-john-thero-on-q1-2014-results-earnings-calltranscript?part=single , accessed April 17, 2019 (ICOSAPENT_DFNDT00016057-67)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2080		Amarin Corporation plc, Fourth Quarter 2012 Earnings Call Transcript, see https://seekingalpha.com/article/1236761-amarin-corporations-ceo-discusses-q4-2012-results-earnings-calltranscript?part=single , accessed April 18, 2019 (ICOSAPENT_DFNDT00015928-37)
1/8/2020		2081		Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2015 (AMRN-PEXP-0005984-6145)
1/8/2020		2082		Amarin Corporation plc, Third Quarter 2013 Earnings Call Transcript, see https://seekingalpha.com/article/1820862-amarins-ceo-discusses-q3-2013-results-earnings-calltranscript?part=single (ICOSAPENT_DFNDT00016043-56)
1/8/2020		2083		Amarin Fourth Quarter 2013 Earnings Call Transcript, see https://seekingalpha.com/article/2057373-amarin-management-discusses-q4-2013-results-earnings-calltranscript?part=single , accessed April 18, 2019 (ICOSAPENT_DFNDT00015938-48)
1/8/2020		2084		https://www.kowapharma.com/products/ , accessed April 16, 2019 (ICOSAPENT_DFNDT00016797-811)
1/8/2020 1/21/2020	1/21/2020	2085	Hofmann	Amarin Corporation plc, First Quarter 2013 Earnings Call Transcript, see https://seekingalpha.com/article/1421861-amarin-corporation-ceo-discusses-q1-2013-results-earnings-call-transcript?part=single , accessed April 26, 2019

Date Marked	Date Admitted	Number	Witness	Description
				(ICOSAPENT_DFNDT00015856-68)
1/8/2020		2086		Amarin Corporation plc, Second Quarter 2014 Earnings Call Transcript, see https://seekingalpha.com/article/2404405-amarins-amrn-ceo-john-thero-on-q2-2014-results-earnings-calltranscript?part=single , accessed April 28, 2019 (ICOSAPENT_DFNDT00016081-90)
1/8/2020		2087		Amarin Corporation plc, First Quarter 2016 Earnings Call Transcript, see https://seekingalpha.com/article/3971859-amarin-corporations-amrn-ceo-john-thero-q1-2016-results-earnings-calltranscript?part=single , accessed April 23, 2019 (ICOSAPENT_DFNDT00015896-903)
1/8/2020 <i>1/21/2020</i>	<i>1/21/2020</i>	2088	<i>Hofmann</i> <i>subject to redaction</i>	Total Promotional Dollars.xlsx (AMRN-PEXP-0007105)
1/8/2020		2089		Amarin Corporation plc, Second Quarter 2013 Earnings Call Transcript, see https://seekingalpha.com/article/1621292-amarins-ceo-discusses-q2-2013-resultearnings-call-transcript?part=single , accessed April 29, 2019. (ICOSAPENT_DFNDT00016030-42)
1/8/2020		2090		Amarin Corporation plc, First Quarter 2017 Earnings Call Transcript, see https://seekingalpha.com/article/4068455-amarin-corporations-amrn-ceo-john-thero-q1-2017-results-earnings-calltranscript?part=single and https://www.vascepa.com/savings-program , accessed April 5, 2019 (ICOSAPENT_DFNDT00015904-14)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2091		https://www.vascepa.com/savings-program , accessed April 28, 2019 (ICOSAPENT_DFNDT00017601-11)
1/8/2020		2092		Amarin Corporation plc, Fourth Quarter 2016 Earnings Call Transcript, see https://seekingalpha.com/article/4050593-amarin-corporations-amrn-ceo-john-thero-q4-2016-results-earnings-calltranscript?part=single , accessed April 29, 2019 (ICOSAPENT_DFNDT00015915-27)
1/8/2020		2093		Monthly Module Views- Sales (NSP)_1_Jan-02-2019.xlsx, (AMRN-PEXP-0007103)
1/8/2020		2094		Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Product Details for NDA 202057, Vascepa 500MG and Vascepa 1GM, https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=N&Appl_No=202057 , accessed April 22, 2019 (ICOSAPENT_DFNDT00016782-3)
1/8/2020		2095		Amarin Announces Market Introduction of Vascepa 01.24.2013, https://investor.amarincorp.com/news-releases/news-release-details/amarin-announces-market-introductionvascepar-icosapent-ethyl , accessed April 23, 2019. (ICOSAPENT_DFNDT00015853-55)
1/8/2020		2096		Amarin Pure EPA Vascepa Now Available 10.25.2016, https://investor.amarincorp.com/news-releases/news-release-details/pure-epavascepar-now-available-new

Date Marked	Date Admitted	Number	Witness	Description
				smaller-half-gram-capsule, accessed April 23, 2019. (ICOSAPENT_DFNDT00015850-52)
1/8/2020		2097		Antara-Drugs@FDA: FDA Approved Drug Products, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.proc&ApplNo=021695 (ICOSAPENT_DFNDT00016140-42)
1/8/2020		2098		Fenoglide, Drugs@FDA: FDA Drug Products, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.proc&ApplNo=022118 , accessed April 24, 2019. (ICOSAPENT_DFNDT00016312-13)
1/8/2020		2099		Lovaza® FDA Label (revised 05/2014), see https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021654s041lbl.pdf
1/8/2020		2100		https://www.gsk.com/media/2682/annual-report-2007.pdf (ICOSAPENT_DFNDTS00016342-525)
1/8/2020		2101		Bays, et al. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev. Cardiovasc. Ther. 6(3): 391-409 (2008) (AMRN00206290-308)
1/8/2020	1/13/2020	2102		Bays, et al. Rationale for Prescription Omega-3-Acid Ethyl Ester Therapy for Hypertriglyceridemia: A Primer for Clinicians. Drugs of Today 44(3): 205-246 (March 2008) (AMRN00290221-264)
	<i>same as 919 Stipulated</i>			
1/8/2020		2103		High Cholesterol/Very High Triglycerides.

Date Marked	Date Admitted	Number	Witness	Description
				https://www.cardiosmart.org/Heart-Conditions/High-Cholesterol/High-Cholesterol-Home/Very-High-Triglycerides (AMRN-PEXP-0000366)
1/8/2020 1/13/2020	1/13/2020	2104	Ketchum	Amarin Pharma, Inc. Citizen Petition to FDA (AMRN03024268-80)
				FDA Letter responding to Amarin Citizen Petition (AMRN01408774-784)
1/8/2020 1/17/2020	1/17/2020	2106	Fisher	Transcript of Endocrinologic and Metabolic Drugs Advisory Committee Meeting, Oct. 16, 2013 (AMRN00112253)
1/8/2020		2107		Jacobson et al., Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review, J. Clin. Lipid. 6(1):5-18 (2012) (AMRN00302233)
1/8/2020		2108		Jan. 9, 2014 Comparative Literature Review of Statin Add-On Therapies Conducted by Amarin Pharma for the FDA DMEP (2014) (AMRN00540152)
1/8/2020		2109		Otvos, J. D. et al., Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial, Circulation;113, (2006) (AMRN00934595)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2110		American Diabetes Association Dyslipidemia Management in Adults with Diabetes, Diabetes Care, 27(Supp. 1) S68-S71 (2004) (AMRN01213101)
1/8/2020		2111		Downs, J. R. et al., Primary Prevention of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels: Results of (AFCAPS/TexCAPS), JAMA;279(20); (1998) (AMRN01235590)
1/8/2020		2112		Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo- controlled trial, The Lancet 361 (2003) (AMRN01382864)
1/8/2020		2113		Miller et al., Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association, Circulation 2011;123:00- 00 (2011) (AMRN02283764)
1/8/2020		2114		7/26/2012 Amarin Press Release (AMRN02488139)
1/8/2020		2115		Thies F. et al., Association of n-3 Polyunsaturated Fatty Acids with Stability of Atherosclerotic Plaques: a Randomised Controlled Trial, The Lancet, 361(9356) (2003) (AMRN02993597)
1/8/2020		2116		FDA Medical Review (AMRN03105942)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2117		Oct. 16, 2013 Amarin Briefing Materials Document for the Endocrinologic and Metabolic Drugs Advisory Committee (EDMAC) (2013) (AMRN03106618)
1/8/2020		2118		Mason et al., Eicosapentaenoic Acid Inhibits Oxidation of ApoB Containing Lipoprotein Particles of Different Size In-Vitro when Administered Alone or in Combination with Atorvastatin Active Metabolite Compared with Other Triglyceride-Lowering Agents, 68 J. Cardiovasc. Pharmacol. 33-39 (2016) (AMRN03130052)
1/8/2020		2119		Ballantyne, et al., Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients with Persistent High Triglycerides (from the ANCHOR Study), Am. J. Cardiol. 110:984-992 (2012) (AMRN03144838)
1/8/2020		2120		Ginsberg et al., Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus, 362 NEJM 1563, 1563 (2010) (AMRN03146139)
1/8/2020		2121		Supplementary Appendix to Bhatt (AMRN03164735)
1/8/2020		2122		Clinical Study Report: A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR 101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease REDUCE-IT (Reduction of

Date Marked	Date Admitted	Number	Witness	Description
				Cardiovascular Events with EPA – Intervention Trial (Feb. 27, 2019) (“REDUCE-IT Study Report”) (AMRN03168530)
1/8/2020		2123		American Diabetes Association Standards of Medical Care in Diabetes, Diabetes Care, 32(Supp. 1) S13-S61 (2009) (AMRN-PEXP-0000722)
1/8/2020 1/17/2020	1/17/2020	2124	Fisher	American Diabetes Association Standards of Medical Care in Diabetes, Diabetes Care, 42(Supp. 1) S1-S193 (2019) (AMRN-PEXP-0007748)
1/8/2020		2125		Leading a New Paradigm in Cardiovascular Health Management (2/16/2017) https://investor.amarincorp.com/static-files/9c8a04ec-dda7-4e68-a52b-418a7a378f01 (ICOSAPENT_DFNDT00017769-79)
1/8/2020 1/17/2020	1/17/2020	2126	Fisher	Elam et al., The ACCORD-Lipid Study: Implications for Treatment of Dyslipidemia in Type 2 Diabetes Mellitus, Clin Lipidol. 691) (2011) 9-20 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509601/pdf/nihms296246.pdf (ICOSAPENT_DFNDT00017840-61)
1/8/2020		2127		Pure EPA Vascepa® Now Available in New, Smaller Half-Gram Capsule Size, available at https://investor.amarincorp.com/static-files/17ffc8ce-9628-4950-bf43-c83866820f4e (ICOSAPENT_DFNDT00018001-03)
1/8/2020		2128		2019 ACC/AHA Multi-Society Guidelines at 4, available at https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000678 (ICOSAPENT_DFNDT00017650-747)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2129		LeRoith et al., Treatment of Diabetes in Older Adults: An Endocrine Society Clinical Practice Guideline, <i>J. Clin. Endocrinol. Metab.</i> 104(5):1520-1574 (2019), available at https://academic.oup.com/jcem/article/104/5/1520/5413486 (ICOSAPENT_DFNDT00017935-89)
1/8/2020		2130		Cymet, Tyler, Should We Treat Moderately Elevated Triglycerides?, <i>Am. Fam. Physician</i> 83(3):246-248 (2011), available at https://www.aafp.org/afp/2011/0201/p246.html (ICOSAPENT_DFNDT00017821-22)
1/8/2020		2131		Hartz, et al., Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care, <i>J. Endocr. Soc.</i> 2(6) 497-512 (2018) ("Hartz"), available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961027/pdf/js.2018-00079.pdf (ICOSAPENT_DFNDT00017908-23)
1/8/2020		2132		Complaint, <i>In re Certain Synthetically Produced, Predominantly EPA Omega-3 Products In Ethyl Ester Or Re-esterified Triglyceride Form</i> , 337-TA-3247 (USITC Aug. 30, 2017) (ICOSAPENT_DFNDT00018382-503)
1/8/2020		2133		Amarin Pharma, Inc. v. ITC, No. 2018-1247, 2019 U.S. App. LEXIS 13136 (Fed. Cir. May 1, 2019) (ICOSAPENT_DFNDT00018315-32)
1/8/2020		2134		2019 ADA Guidelines March 27, 2019 Supplement, Section 10, Annotation ("2019 ADA Guidelines Supplement"), available at http://care.diabetesjournals.org/content/42/Supplement_1/S103
1/8/2020		2135		Miller, Michael, Question: Is it safe to combine statins and fibrates? (2007),

Date Marked	Date Admitted	Number	Witness	Description
				available at https://www.medscape.org/viewarticle/563490 (ICOSAPENT_DFNDT00017993-94)
1/8/2020		2136		Shek, et al., Statin-fibrate combination therapy, Ann. Pharmacother. 35(7-8):908-17 (2001), available at https://www.ncbi.nlm.nih.gov/pubmed/11485144 (ICOSAPENT_DFNDT00018004-05)
				Berglund et al., Treatment Options for Hypertriglyceridemia: from Risk Reduction to Pancreatitis, Best Pract Res Clin Endocrinol Metab. 28(3):423-427 available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028601/ (ICOSAPENT_DFNDT00016834-43)
1/8/2020		2138		Kris-Etherton, P. M. et al., Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease, Circulatoin 106:2747-2757, available at https://www.ahajournals.org/doi/full/10.1161/01.CIR.0000038493.65177.94 ; impeachment (ICOSAPENT_DFNDT00017924-34)
1/8/2020 1/17/2020	1/17/2020	2139	Fisher	Dr. Matthew Budoff, Understanding How Vascepa Fits in the Prescription-Based, Pure EPA Market in Treating Hypertriglyceridemia, Slingshot Insights (2017) 1-15 (ICOSAPENT_DFNDT00018048-62)
1/8/2020 1/17/2020	1/17/2020	2140	Fisher	Dr. Matthew Budoff, Preparing for Amarin's REDUCE-IT Data Read Out for Vascepa in Patients with Elevated Cardiovascular Risk, Slingshot Insights (2018) (ICOSAPENT_DFNDT00017823-39)
1/8/2020		2141		Brinton, E. A. and Mason, R. P., Prescription Omega-3 Fatty Acid

Date Marked	Date Admitted	Number	Witness	Description
				Products Containing Highly Purified Eicosapentaenoic Acid (EPA), Lipids in Health and Disease, 16(1) (2017) available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282870/ (ICOSAPENT_DFNDT00017808-20)
1/8/2020 1/17/2020	1/17/2020	2142	Fisher	What is Amarin's Opinion on the ASCEND Clinical Trial (2018), available at https://investor.amarincorp.com/static-files/7cb6fad5-e22b-4d15-98b9-28eb4c43f95f (ICOSAPENT_DFNDT00018045-47)
				Terano, T. et al., Eicosapentaenoic Acid as a Modulator of Inflammation, Biochemical Pharmacology, 35(5), (1986) 779-785 (ICOSAPENT_DFNDT00016823-29)
1/8/2020 1/17/2020	1/17/2020	2143	Fisher	Surette, M. E., The Science Behind Dietary Omega-3 Fatty Acids, CMAJ, 178(2)(2008) 177-180, available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2174995/pdf/20080115s00023p177.pdf (ICOSAPENT_DFNDT00018024-27)
1/8/2020 1/17/2020	1/17/2020	2145	Fisher	Omura, M. et al., Eicosapentaenoic Acid (EPA) Induces Ca ²⁺ -Independent Activation and Translocation of Endothelial Nitric Oxide Synthase and Endothelium-Dependent Vasorelaxation, FEBS Letters, 487(3), 361-366 (2001) available at https://febs.onlinelibrary.wiley.com/doi/epdf/10.1016/S0014-5793%2800%2902351-6 (ICOSAPENT_DFNDT00017995-8000)
1/8/2020 1/17/2020	1/17/2020	2146	Fisher	Suzuki, T. et al., Eicosapentaenoic Acid Protects Endothelial Cells Against

Date Marked	Date Admitted	Number	Witness	Description
				Anoikis Through Restoration of cFLIP, Hypertension, 42, 342-348 (2003) available at https://www.ahajournals.org/doi/pdf/10.1161/01.HYP.0000084602.06114.AD (ICOSAPENT DFNDT00018028-34)
1/8/2020		2147		Executed Research Proposal, Comparative Inhibition of Oxidation for EPA versus DHA and an EPA/DHA Combination in High Density Lipoproteins (HDL) (AMRN03171442-52)
1/8/2020		2148		Research Agreement between Amarin, APIL and Elucida (AMRN03171453-70)
1/8/2020		2149		Executed Research Proposal, Comparative Inhibition of Oxidation for EPA versus DHA in Small Dense LDL (sdLDL): A Kinetics Analysis between Amarin and Elucida (AMRN03171471-77)
1/8/2020		2150		Executed Research Proposal, Comparative Effects of Eicosapentaenoic Acid (EPA) versus Docosahexaenoic Acid (DHA) Human Endothelial Function between Amarin and Elucida (AMRN03171478-86)
1/8/2020		2151		Executed Schedule 1: Services -- Extension # 1 between Amarin and Elucida(AMRN03171487-88)
1/8/2020		2152		Executed Research Proposal, Effects of Eicosapentaenoic Acid (EPA) and Statins on Human Endothelial Function and Nitric Oxide Release: Basis for Synergistic Actions between Amarin and Elucida (AMRN03171489-99)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2153		Executed Research Services Agreement, Comparative Effects of Eicosapentaenoic Acid (EPA), Docosapentaenoic Acid (DPA) versus Docosahexaenoic Acid (DHA) and EPA/DHA on Membrane Domains: X-ray Diffraction Analysis between Amarin and Elucida (AMRN03171500-5120)
1/8/2020		2154		Executed Research Services Agreement, Synergistic Effects of Eicosapentaenoic Acid (EPA) and Statins in Human Endothelial Function, Schedule 1: Services between Amarin and Elucida (AMRN03171513-522)
1/8/2020		2155		Executed Research Proposal, Comparative Effects of Eicosapentaenoic Acid (EPA) versus Docosahexaenoic Acid (DHA) and EPA/DHA on Membrane Domains: X-ray Diffraction Analysis, Schedule 1: Services between Amarin and Elucida (AMRN03171523-31)
1/8/2020		2156		Executed Research Proposal, Effects of Eicosapentaenoic Acid (EPA) on Cholesterol Crystal Domains in Membranes with Hyperglycemia: X-ray Diffraction Study, Schedule 1: Services between Amarin and Elucida (AMRN03171532-44)
1/8/2020		2157		Executed Research Proposal, Inhibition of Oxidation by Eicosapentaenoic Acid (EPA) in Human LDL Subfractions: A Focus on Small Dense LDL between Amarin and Elucida (AMRN03171545-55)
1/8/2020		2158		Executed Research Proposal, Comparative Effects of Eicosapentaenoic Acid (EPA), Fenofibrate, Niacin, and Gemfibrozil - Alone or in Combination with Statins - on Oxidation of Small Dense and

Date Marked	Date Admitted	Number	Witness	Description
				Unfractionated Human Low Density Lipoprotein (LDL) between Amarin and Elucida(AMRN03171556-69)
1/8/2020		2159		Executed Research Proposal, Effects of Eicosapentaenoic Acid (EPA) versus Docosahexaenoic Acid (DHA), Fenofibrate, Niacin, and Gemfibrozil on Disruption of Established Membrane Cholesterol Domains between Amarin and Elucida (AMRN03171570-79)
1/8/2020		2160		Executed Research Proposal, Effects of Small Dense LDL on Human Endothelial Function after Treatment with Eicosapentaenoic Acid (EPA) - Alone or in Combination with Statin - Versus Fenofibrate, Niacin, Gemfibrozil and Docosahexaenoic Acid (DHA) Under Conditions of Oxidative Stress and more between Amarin and Elucida (AMRN03171580-90)
1/8/2020		2161		Executed Research Proposal, Comparative Effects of Eicosapentaenoic Acid (EPA), Docosahexanoic Acid (DHA), Fenofibrate, Niacin, Gemfibrozil - Alone or in Combination with Atorvastatin Metabolite - on Human Endothelial Function Following Exposure to oxLDL between Amarin and Elucida (AMRN03171591-605)
1/8/2020		2162		Executed Research Proposal for Completion of BBA Manuscript, Dose-Dependent Effects of Vascepa between Amarin and Elucida (AMRN03171606-617)
1/8/2020		2163		Executed Research Proposal, Comparative Effects of

Date Marked	Date Admitted	Number	Witness	Description
				Eicosapentaenoic Acid (EPA), Fenofibrate, Niacin, and Gemfibrozil - Alone or in Combination with Select Statins - on Lipid Peroxidation in Model Membranes Exposed to Hyperglycemic Conditions and more between Amarin and Elucida (AMRN03171618-29)
1/8/2020		2164		Executed Research Proposal, Distinct Effect of EPA Plus/Minus Atorvastatin Active Metabolite on Inhibiting Rat Glomerular Endothelial Dysfunction with Hyperglycemia and oxLDL Ex Vivo: Comparison to other TG-Lowering Agents and DHA between Amarin and Elucida (AMRN03171630-639)
				Executed Research Proposal, Comparative Effects of EPA vs DHA on membrane Lipid Dynamics and Structure: Fluorescence Anisotropy and X-Ray Diffraction Analyses between Amarin and Elucida (AMRN03171640-58)
1/8/2020		2166		Executed Research Proposal, Time-Dependent Effects of Eicosapentaenoic Acid (EPA) Pretreatment of HUVECS - Alone or in Combination with Atorvastatin Metabolite - versus Docosahexaenoic Acid (DHA), Fenofibrate, Niacin and Gemfibrozil on Endothelial Function with Oxidized LDL Exposure and more between Amarin and Elucida (AMRN03171659-69)
1/8/2020		2167		Executed Research Proposal, Dose Dependent Effects of Eicosapentaenoic Acid (EPA) on Disruption of Established Membrane Cholesterol Domains (AMRN03171670-78)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2168		Executed Research Proposal, Comparative Effects of Eicosapentaenoic Acid (EPA) plus/minus Atorvastatin Active Metabolite (ATM) on Oxidation of Small Dense Human Low Density Lipoprotein (sdLDL) with Hyperglycemia (AMRN03171679-88)
1/8/2020		2169		Executed Research Proposal, Comparative Effects of EPA, DHA, Niacin, Fenofibrate and Vitamin E on Membrane Oxidation over a Broad Cholesterol Range under conditions of Hyperglycemia and more (AMRN03171689-97)
1/8/2020		2170		Executed Research Proposal, Comparative and Time-Dependent Effects of Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA), EPA/DHA Combination and Vitamin E on sdLDL Oxidation(AMRN03171698-704)
1/8/2020		2171	,	Executed Research Proposal, Effects of Eicosapentaenoic Acid (EPA) - Alone or in Combination with the ortho-hydroxy metabolite of Atorvastatin and more (AMRN03171705-13)
1/8/2020		2172		Executed Schedule 1 to The Research Services Agreement Between Amarin, APIL, and Elucida (AMRN03171714-20)
1/8/2020		2173		Executed Schedule 1 to The Research Services Agreement Between Amarin, APIL, and Elucida (AMRN03171721-31)
1/8/2020		2174		Executed Services Agreement between Amarin and R. Preston Mason for

Date Marked	Date Admitted	Number	Witness	Description
				10/20/2015 - 10/26/2015 (AMRN03171732-34)
1/8/2020		2175		Amendment # 1 to The Research Services Agreement between Amarin, APIL, and Elucida (AMRN03171735-37)
				Amarin Confidentiality Agreement between Amarin and R. Preston Mason (AMRN03171738-40)
1/8/2020		2177		Executed Schedule 1 Services (AMRN03171741-42)
1/8/2020		2178		Consultancy Agreement between Amarin and R. Preston Mason (AMRN03171743-51)
1/8/2020		2179		Services Agreement between Amarin and R. Preston Mason for 4/14/2016 - 6/30/2016 (AMRN03171752-56)
1/8/2020		2180		Services Agreement between Amarin and R. Preston Mason for 10/1/2015 - 11/6/2015 (AMRN03171757-59)
1/8/2020		2181		Mutual Confidentiality Agreement between Amarin and R. Preston Mason(AMRN03171760-62)
1/8/2020		2182		Amendment # 1 to The Research Services Agreement between Amarin,

Date Marked	Date Admitted	Number	Witness	Description
				APIL, and Elucida (AMRN03171763-83)
1/8/2020		2183		Executed IIT Study Review & Support Agreement Form - EPA Preserves HDL and Endothelial Function (AMRN03171784)
				Executed IIT Study Review & Support Agreement Form - Comparative Inhibition of Oxidation for EPA versus DHA and an EPA/DHA Combination in High Density Lipoproteins (HDL) (AMRN03171785)
1/8/2020		2185		Services Agreement between Amarin and R. Preston Mason for 12/9/2016 - 1/15/2017 (AMRN03171786-90)
1/8/2020		2186		Services Agreement between Amarin and R. Preston Mason for 12/9/2016 - 1/15/2017 (AMRN03171791-95)
1/8/2020		2187		W-9 Form for Elucida Research LLC (AMRN03171796-804)
				Executed Research Proposal, Comparative and Time-Dependent Effects of Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA), EPA/DHA Combination and Vitamin E on sdLDL Oxidation (AMRN03171805-11)
1/8/2020		2189		Executed Schedule 1 to The Research Services Agreement Between Amarin,

Date Marked	Date Admitted	Number	Witness	Description
				APIL, and Elucida - Comparative Inhibition of Eicosapentenoic Acid (EPA) versus Similar Fatty Acid on Membrane Oxidation - Addendum for Additional cholesterol crystal domain investigations (phase 2c) (AMRN03171812-15)
1/8/2020		2190		Executed Schedule I to The Research Services Agreement Between Amarin, APIL, and Elucida - Effects Eicosapentenoic Acid (EPA) in Combination with Atorvastatin and Compared to Docosahexanoic Acid (DHA) on Human Endothelial Cell Dysfunction Caused by Lipolzed TG-Rich Lipoprotein (VLDL)(AMRN03171816-20)
1/8/2020		2191		Executed Schedule I to The Research Services Agreement Between Amarin, APIL, and Elucida - Comparative Inhibition of Eicosapentenoic Acid (EPA) versus Similar Fatty Acid on Membrane Oxidation (AMRN03171821-32)
1/8/2020		2192		Executed Schedule I to The Research Services Agreement Between Amarin, APIL, and Elucida - Comparative Inhibition of Oxidation for EPA versus ETE, AA, EA, DHA, DPA, ALA, OA, LA, and SA in Human Small Dense LDL (sdLDL) (AMRN03171833-45)
1/8/2020		2193		Services Agreement between Amarin and R. Preston Mason for 1/1/2016 - 1/31/2016 (AMRN03171846-48)
1/8/2020		2194		Executed Research Proposal, Comparative Effects of Eicosapentaenoic Acid (EPA), Fenofibrate, Niacin, and Gemfibrozil - Alone or in Combination with Select

Date Marked	Date Admitted	Number	Witness	Description
				Statins - on Lipid Peroxidation in Model Membranes Exposed to Hyperglycemic Conditions and more between Amarin and Elucida (AMRN03171849-60)
1/8/2020		2195		Executed Schedule 1 to The Research Services Agreement Between Amarin, APIL, and Elucida - Effects of Eicosapentenoic Acid (EPA) on Human LDL and Model Membrane Oxidation: A Dose - ranging Analysis of Potential Threshold Activity in Vitro - Addendum for additional aliquotes, timepoints and concentrations (AMRN03171861-65)
1/8/2020		2196		Executed Research Proposal, Effects of Eicosapentenoic Acid (EPA) on Human LDL and Model Membrane Oxidation (AMRN03171866-79)
1/8/2020		2197		Executed Schedules between APIL, Amarin, and Elucida (AMRN03171880-81)
1/8/2020		2198		Executed Research Proposal, Comparative and Time-Dependent Effects of sdLDL Treated with either Eicosapentaenoic Acid (EPA) or Docosahexanoic Acid (DHA) under Oxidative Stress Conditions on Human Endothelial Function (AMRN03171882-94)
1/8/2020		2199		Ando, Eicosapent Acid Reduces Plasma Levels of Remnant Lipoproteins and Prevents in Vivo Peroxidation of LDL in Dialysis Patients. J Am Nephrol 10:2177 (1999) (ICOSAPENT_DFDT00007276-83)
1/8/2020		2200		Chan, et al. Factorial study of the effects of atorvastatin and fish oil on

Date Marked	Date Admitted	Number	Witness	Description
				dyslipidaemia in visceral obesity. European Journal of Clinical Investigation 32:429-436 (2002) (ICOSAPENT_DFDTS00005926-35)
1/8/2020		2201		Contacos, et al. Effect of Pravastatin and w-3 Fatty Acids on Plasma Lipids and Lipoproteins in Patients With Combined Hyperlipidemia. Arterioscler Thromb Vasc Biol. 13:1755-1762 (1993) (ICOSAPENT_DFDTS00005944-52)
1/8/2020		2202		European Patent Application EP 0 273 708 A2 (ICOSAPENT_DFDTS00005953-76)
1/8/2020		2203		European Patent Application EP 0 277 747 A2 (ICOSAPENT_DFDTS00005977-83)
1/8/2020		2204		European Patent Application EP 0 347 509 A1 (ICOSAPENT_DFDTS00005984-96)
1/8/2020		2205		Kelley et al., Docosahexaenoic Acid Supplementation Improves Fasting and Postprandial Lipid Profiles in Hypertriglyceridemic Men, pp. 324-333, Clinical Nutrition, Volume 86, No. 2 (August 2007) (ICOSAPENT_DENDTS00006201-6212)
1/8/2020		2206		Leigh-Firbank, et al, Eicosapentaenoic Acid and Docosahexaenic Acid from Fish Oils: Differential Associations with Lipid Responses, British Journal of Nutrition (2002), Volume 87, pp. 435-445. (ICOSAPENT_DFNCTS00006245-55)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2207		Lovegrove, et al., Moderate Fish-oil Supplementation Reverses Low-Platelet, Long-chain n-3 Polyunsaturated Fatty Acid Status and Reduces Plasma Triacylglycerol Concentrations in British Indo-Asians, Clinical Nutrition Volume 79, pp. 974-982 (2004) (ICOSAPENT_DFNDTS00006383-91)
1/8/2020		2208		Mataki, et al., Effect of Eicosapentaenoic Acid in Combination with HMG-CoA Reductase Inhibitor on Lipid Metabolism, International Medical Journal, Vol. 5, No. 1, pp. 35-36 (March 1998) (ICOSAPENT_DFNDTS00006437-39)
1/8/2020		2209		Pownall, et al., Correlation of Serum Triglyceride and Its Reduction by ω-3 Fatty Acids with Lipid Transfer Activity and the Neutral Lipid Compositions of High-density and Low-density Lipoproteins, Atherosclerosis (1998) (ICOSAPENT_DFNDTS00011379-91)
1/8/2020		2210		Theobald, et al., LDL Cholesterol-raising Effect of Low-dose Docosahexaenoic Acid in Middle-aged Men and Women, Clinical Nutrition, Volume 79, No. 4, pp. 558-563 (April 2004) (ICOSAPENT_DFNDTS00006905-12)
1/8/2020		2211		U.S. Patent 5,215,630 (ICOSAPENT_DFDTS00012204-214)
1/8/2020		2212		U.S. Patent 5,840,944 (ICOSAPENT_DFDTS00012337-343)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2213		U.S. Patent 6,303,330 (ICOSAPENT_DFDTS00005855-62)
1/8/2020		2214		U.S. Patent 6,384,077 (ICOSAPENT_DFDTS00007000-13)
1/8/2020		2215		U.S. Patent 6,846,942 (ICOSAPENT_DFDTS00005863-67)
1/8/2020		2216		U.S. Patent Application Publication 2003/0104048(ICOSAPENT_DFDTS0 0006913-45)
1/8/2020		2217		U.S. Patent Application Publication 2006/0134178 (ICOSAPENT_DFDTS00006946-63)
1/8/2020		2218		Virani and Nambi, The Role of Lipoprotein-associated Phospholipase A2 As a Marker for Atherosclerosis. Current Atherosclerosis Reports 9:97- 103 (ICOSAPENT_DFDTS00007014-20)
1/8/2020	1/13/2020	2219		Rader, Lipid Disorders. In Textbook of Cardiovascular Medicine, Chapter 5 (3d ed. 2007) (AMRN0290951-973)
1/8/2020		2220		Stipulated - Same as 827 Sanders, Triglyceride-Lowering Effect of Marine Polyunsaturates in Patients with Hypertriglyceridemia. Arteriosclerosis 5:459-465 (1985) (AMRN0291030-1036)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2221		Nicholas P. Godici Curriculum Vitae
1/8/2020 1/16/2020	1/15/2020	2222	Heinecke	Jay W. Heinecke, M.D. Curriculum Vitae
1/8/2020 1/21/2020	1/21/2020	2223	Hofmann	Ivan T. Hofmann Curriculum Vitae
1/8/2020		2224		John Kornak, PhD Curriculum Vitae
1/8/2020 1/14/2020	1/14/2020	2225	Scheinberg	Jonathan I. Scheinberg, MD, FACC Curriculum Vitae
1/8/2020 1/13/2020	1/13/2020	2226	Ketchum	Endocrinologic and Metabolic Drugs Advisory Committee Briefing Document: Vascepa® REDUCE-IT® (Reduction of Cardiovascular Events with EPA - Intervention Trial)
1/8/2020		2227		Errata to the Amarin Pharmaceutical Ireland Limited (Amarin) Briefing Document for the Advisory Committee meeting on 14 November 2019.
1/8/2020		2228		FDA Briefing Document, Endocrinologic and Metabolic Drugs, Advisory Committee Meeting, November 14, 2019

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2229		Erratum to FDA Briefing Document: Endocrinologic and Metabolic Drugs Advisory Committee (EDMAC) Meeting, November 14, 2019
1/8/2020		2230		Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Roster
1/8/2020		2231		Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting, November 14, 2019, Draft Agenda
1/8/2020		2232		Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting, November 14, 2019, Draft Meeting Roster
1/8/2020		2233		Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting, November 14, 2019, Draft Questions
1/8/2020		2234		November 14, 2019 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) - Webcast Information
1/8/2020 11/13/2020	11/13/2020	2235	Ketcham	Icosapent Ethyl (VASCEPA®): Amarin Pharmaceuticals Presentation to the Endocrinologic and Metabolic Drugs Advisory Committee, NDA 202057
1/8/2020		2236		FDA Introductory Remarks, Endocrinologic and Metabolic Drugs,

Date Marked	Date Admitted	Number	Witness	Description
				Advisory Committee (EMDAC) Meeting, John Sharretts, M.D.
1/8/2020		2237		Plaintiffs' Responses and Objections to Defendants' Joint First Set of Interrogatories to Amarin (Nos. 1-8)
1/8/2020		2238		November 14, 2019, Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) - Webcast Recording, Start of Meeting to Morning Break. https://collaboration.fda.gov/poku8qu000zj/?launcher=false&fcsContent=true&pbMode=normal
1/8/2020		2239		November 14, 2019, Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) - Webcast Recording, Morning Break to Afternoon Break. https://collaboration.fda.gov/pgu58b2olhgv/?launcher=false&fcsContent=true&pbMode=normal
1/8/2020		2240		November 14, 2019, Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) - Webcast Recording, Afternoon Break to End of Meeting. https://collaboration.fda.gov/pegit9sba12n/?launcher=false&fcsContent=true&pbMode=normal
1/8/2020 1/13/2020	1/13/2020	2241	Ketchum	AMRN00731643 Metadata
1/8/2020		2242		Vascepa sNDA annotated label (AMRN03174152-3174172)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2243		Vascepa sNDA approval (AMRN03174932-3174950)
1/8/2020		2244		Vascepa sNDA Clinical Overview(AMRN03174702-3174749)
1/8/2020		2245		Vascepa sNDA Clinical Pharmacology (AMRN03174826-3174835)
1/8/2020 1/14/2020	1/14/2020	2246	Burns	Vascepa sNDA Financial Disclosure (AMRN03174601-3174666)
1/8/2020 1/13/2020	1/13/2020	2247	Ketchum	Vascepa sNDA label (AMRN03174410-3174423)
1/8/2020 1/13/2020	1/13/2020	2248	Ketchum	Vascepa sNDA label (AMRN03174954-3174967)
1/8/2020		2249		Vascepa sNDA labeling correspondence (AMRN03175000-3175298)
1/8/2020 1/13/2020	1/13/2020	2250	Ketchum	Vascepa sNDA patent forms (AMRN03174514-3174597)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2251		Vascepa sNDA Reviewer Guide (AMRN03174505-3174513)
1/8/2020 1/13/2020	1/13/2020	2252	Ketchum	Vascepa sNDA Summary of Clinical Efficacy (AMRN03174762-3174825)
1/8/2020		2253		Amarin News - General Release - Amarin Announces FDA Award of Three-Year Exclusivity for Vascepa® (icosapent ethyl) Capsules (WWICO-NV-148504-148506)
1/8/2020		2254		VASCEPA - Exclusivity Determination
1/8/2020 1/13/2020	1/13/2020	2255	Ketchum	Amarin News - General Release - Amarin Announces FDA New Chemical Entity Market Exclusivity Determination for Vascepa® (icosapent ethyl) Capsules
1/8/2020 1/13/2020	1/13/2020	2256		Icosapent Ethyl 1g Capsules Labeling (WWICO-NV-162529-162539)
	<i>same as 1203 stipulated</i>			
1/8/2020 1/13/2020		2257		RLD Side-By-Side Comparison (WWICO-NV-162550-162564)
	<i>same as 1204 stipulated</i>			
1/8/2020 1/28/2020	1/28/2020	2258	Toth	Woodman, et al., Docosahexaenoic Acid but Not Eicosapentaenoic Acid

Date Marked	Date Admitted	Number	Witness	Description
				Increases LDL Particle Size in Treated Hypertensive Type 2 Diabetic Patients, 26 Diabetes Care 253 (2003) ("Woodman 2003b") (AMRN01066627)
1/8/2020		2259		Woodman, et al., Effects of Purified Eicosapentaenoic Acid and Docosahexaenoic Acid on Platelet, Fibrinolytic and Vascular Function in Type 2 Diabetic Patients, 166 Atherosclerosis 85 (2003) ("Woodman 2003a") (AMRN01172851-1172859)
1/8/2020		2260		Mori et al., Docosahexaenoic Acid but Not Eicosapentaenoic Acid Lowers Ambulatory Blood Pressure and Heart Rate in Humans, 34 Hypertension 253 (1999) ("Mori 1999") (AMRN01177185-1177193)
1/8/2020		2261		Hamazaki et al., Docosahexaenoic Acid-Rich Fish Oil Does Not Affect Serum Lipid Concentrations of Normolipidemic Young Adults, 126 J. Nutrition 2784 (1996) ("Hamazaki") (AMRN-PEXP-0007332-7337)
1/8/2020		2262		Nelson el al., The Effect of Dietary Docosahexaenoic Acid on Plasma Lipoproteins and Tissue Fatty Acid Composition in Humans, 32 Lipids 1137 (1997) ("Nelson") (AMRN00290858-290867)
1/8/2020 1/28/2020	1/28/2020	2263	Tork	Woodman et al., Effects of Purified Eicosapentaenoic and Docosahexaenoic Acids on Glycemic Control, Blood Pressure, and Serum Lipids in Type 2 Diabetic Patients with Treated Hypertension, 76 Am. J. Clinical Nutrition 1007 (2002) ("Woodman 2002") (AMRN00291334-291342)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020 1/28/2020	1/28/2020	2264	Toth	Grimsgaard et al., Effects of Highly Purified Eicosapentaenoic Acid and Docosahexaenoic Acid on Hemodynamics in Humans, 68 Am. J. Clinical Nutrition 52 (1998) ("Grimsgaard 1998") (ICOSAPENT-DFNDTS00009272-9279)
1/8/2020		2265		AMRN01171835-1171859 Metadata
1/11/2020 1/14/2020	1/14/2020	2266	Scheinberg	Icosapent Ethyl Labeling (DRLEEEPA 0138136-47)
1/11/2020 1/13/2020	1/13/2020	2267	Kitchum	Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: Patent and Exclusivity for: N202057
1/11/2020		2268		Braeckman, R. et al., Pharmacokinetics of Eicosapentaenoic Acid in Plasma and Red Blood Cells After Multiple Oral Dosing With Icosapent Ethyl in Healthy Subjects, Clin. Pharm. Drug Dev. 3(2) 101-108 (2013) (AMRN00509635-42)
1/11/2020		2269		INTENTIONALLY LEFT BLANK
1/11/2020		2270		INTENTIONALLY LEFT BLANK

Date Marked	Date Admitted	Number	Witness	Description
1/11/2020		2271		INTENTIONALLY LEFT BLANK
1/11/2020		2272		Elucida 2014 Form 1099 (AMRN03172197)
1/11/2020		2273		Elucida 2015 Form 1099 (AMRN03172198)
1/11/2020		2274		Elucida 2016 Form 1099 (AMRN03172199)
1/11/2020		2275		Elucida 2017 Form 1099 (AMRN03172200)
1/11/2020		2276		Elucida 2018 Form 1099 (AMRN03172201)
1/11/2020		2277		INTENTIONALLY LEFT BLANK
1/11/2020		2278		Email between Mason and Stirtan re ACC Meeting with Preston Mason (2 pm Sat, Hyatt at Convention Center) (AMRN02915182-87)
1/11/2020		2279		INTENTIONALLY LEFT BLANK
1/11/2020		2280		Email between Rowe and Mason re Amarin 2009 Project Protocol (AMRN02198423-24)

Date Marked	Date Admitted	Number	Witness	Description
1/11/2020		2281		Email between Rowe and Johnson re FW: Amarin 2009 Project Protocol (AMRN02198704-05)
1/11/2020		2282		Email between Mason and Rowe re Looks like we can combine our interests (AMRN02187317)
1/11/2020		2283		Amarin, How Does Vascepa Work? Potential Mechanisms of Action for Vascepa, available at https://amarincorp.gcs-web.com/static-files/65fd97af-7f3e-483a-b408-a402b82ad1fb
1/11/2020		2284		Email between Manku, Cunningham, Holmes, Cooke re FW: ISSFAL meeting abstracts (AMRN00638718-19)
1/11/2020		2285		ISSFAL 2006 Abstracts – Tuesday 25 July: Concurrent Session 15 – Cardiac Composition (AMRN00638745)
1/11/2020		2286		Matsumoto et al., Orally administered eicosapentaeonoic acid reduces and stabilizes atherosclerotic lesions in ApoE-deficient mice, Atherosclerosis 197 (2008) 524-533 (AMRN02192103-112)
1/11/2020		2287		Calder, OCEAN: Omacor Carotid Endarterectomy Intervention Trial (AMRN01688530-33)
1/11/2020		2288		Nobukata et al., Long-Term Administration of Highly Purified Eicosapentaenoic Acid Ethyl Ester Prevents Diabetes and Abnormalities of Blood Coagulation in Male WBN/Kob Rats, Metabolism 49:7, 912-919 (2000) (AMRN01645981-88)
1/11/2020		2289		Email between Philip, Stirtan, Ketchum, Juliano, Copland, Berg,

Date Marked	Date Admitted	Number	Witness	Description
				Bronson, Galdo, Chowdhury re Slide decks from Mason/Djousse Mtg (AMRN00889648)
1/11/2020		2290		INTENTIONALLY LEFT BLANK
1/11/2020		2291		Seph Philip, RPh, PharmD, EPA and Endothelial Function – Clinical Experience & Biomarkers (AMRN00889731-52)
1/11/2020		2292		INTENTIONALLY LEFT BLANK
1/11/2020		2293		INTENTIONALLY LEFT BLANK
1/11/2020		2294		Email between Ketchum, Juliano, Philip re Following today's Telephone Call (AMRN01353860-62)
1/12/2020 <i>1/11/2020</i>	<i>1/11/2020</i>	2295	<i>Fisher</i>	Curriculum Vitae of Edward A. Fisher, M.D., M.P.H., Ph.D.
1/12/2020		2296		INTENTIONALLY LEFT BLANK
1/13/2020		2297		Ketchum Stock Options (2012)
1/13/2020		2298		Yahoo Finance Amarin Stockholders (2020)
1/13/2020 <i>1/21/2020</i>	<i>1/21/2020</i>	2299	<i>Ketchum</i>	Ketchum Summary Exhibit

DEFENDANTS' SUPPLEMENT TO FILED EXHIBIT LIST

Case # 2:16-cv-02525-MMD-NJK

Caption: Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA, Inc., et al.

Exhibits for: Defendants Hikma Pharmaceuticals USA, Inc.; Hikma Pharmaceuticals International Limited; Dr. Reddy's Laboratories, Inc.; and Dr. Reddy's Laboratories, Ltd.

Date Marked	Date Admitted	Number	Witness	Description
1/28/2020	1/28/2020	3000	Toth	Amarin Open Payment Database (2018)
to be redacted				
1/28/2020	1/28/2020	3001	Toth	Amarin Open Payment Database (2017)
to be redacted				
1/28/2020	1/28/2020	3002	Toth	Amarin Open Payment Database (2016)
to be redacted				
1/28/2020	1/28/2020	3003	Toth	Amarin Open Payment Database (2015)
to be redacted				
1/28/2020	1/28/2020	3004	Toth	Amarin Open Payment Database (2014)
1/28/2020	1/28/2020	3005	Toth	Amarin Open Payment Database (2013)
to be redacted				

Date Marked	Date Admitted	Number	Witness	Description
1/28/2020	1/28/2020	3006	Toth	Toth Compensation Summary Exhibit
1/28/2020	1/28/2020	3007	Toth	Lipitor Label 2007
		3008		Toth 2014 Article
1/28/2020		3009	Toth	Endocrinology Advisor_Article_2018_Toth Comments
		3010		Prevalence of US adults with TGs_2019
		3011		High TGS are Associated Toth 2018
		3012		P739 TGs 150 and above associated with an increased risk Toth
		3013		HTG in statin treated US adults Toth
		3014		HTG is associated with increased risk

Date Marked	Date Admitted	Number	Witness	Description
				Toth
				Long-term statin persistence Toth
				Crestor 2007 label
1/28/2020	1/28/2020	3017	Toth	OpenPayment Steps
				Audits and Penalties CMS
				Efficacy and Safety of a New HMG-CoA Reductase Inhibitor
1/29/2020	1/29/2020	3019		Toth-Drug Treatment of Hyperlipidaemia
1/29/2020	1/29/2020	3020	Toth	